SAN DIEGO, CA -- (Marketwired) -- 01/13/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share in connection with its previously announced underwritten public offering of 3,720,000 shares of common stock, bringing the expected total gross proceeds from the offering to approximately $25,454,100, before underwriting discounts and commissions and other offering expenses and before any use of the proceeds by the company. The sale of the additional shares is expected to close on January 16, 2014, subject to customary closing conditions.
CRT Capital Group, LLC acted as sole book-running manager for the offering, and Newport Coast Securities, Inc. acted as co-manager of the offering.
A registration statement on Form S-1 relating to the shares of common stock offered by the company was filed with the Securities and Exchange Commission and is effective. The final prospectus relating to the offering, and any supplements thereto, have been filed with the SEC and are available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus may be obtained from the SEC's web site or from CRT Capital Group LLC, 262 Harbor Drive, Stamford, CT 06902.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company's current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer.